iA Global Asset Management Inc. Sells 3,818 Shares of DexCom, Inc. (NASDAQ:DXCM)

iA Global Asset Management Inc. trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 44,280 shares of the medical device company’s stock after selling 3,818 shares during the period. iA Global Asset Management Inc.’s holdings in DexCom were worth $3,444,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in DXCM. Versant Capital Management Inc bought a new position in shares of DexCom during the fourth quarter valued at $25,000. Private Trust Co. NA lifted its stake in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares during the period. Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the fourth quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of DexCom during the fourth quarter valued at approximately $49,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Kevin R. Sayer sold 32,498 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. The trade was a 8.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is currently owned by insiders.

DexCom Stock Up 2.4 %

NASDAQ DXCM opened at $75.11 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock’s 50 day moving average is $83.41 and its 200 day moving average is $76.92. The stock has a market cap of $29.35 billion, a PE ratio of 52.52, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the topic of several research reports. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Citigroup boosted their price target on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.